Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/ijgc-2020-002288 http://scihub22266oqcxt.onion/10.1136/ijgc-2020-002288 33883231!?!33883231 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33883231&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Int+J+Gynecol+Cancer 2021 ; 31 (8): 1154-1158 Nephropedia Template TP {{tp|p=33883231|t=2021. Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic |pdf=|usr=}}{{33883231}} gab.com Text Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic JO: Int J Gynecol Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33883231 #FOAvip BACKGROUND: During the COVID-19 pandemic, cancer care had to be reorganized; national and international recommendations were published to manage anticancer treatments safely and to reduce the risk of SARS-CoV-2 infection for patients and health workers. OBJECTIVE: To evaluate whether the adoption of recommendations for the management of patients with gynaecologic cancer receiving treatment during the pandemic resulted in containment of infections and continuing oncologic care. METHODS: Based on the published recommendations, and according to the local Health Direction guidelines, we developed and drafted a security protocol to modify access of patients with gynaecologic cancer to the "Fondazione Policlinico Agostino Gemelli-IRCCS, Rome" between February 1 and April 30, 2020 and compared results with the corresponding 3 months of 2019. RESULTS: Between February and April 2019, we registered 3254 admissions, including 2253 patients receiving intravenous chemotherapies, 298 receiving oral therapies, and 703 having hospital visits. Between February and April 2020, we registered 3213 admissions, including 2221 patients receiving intravenous chemotherapies, 401 receiving oral therapies, and 591 having hospital visits. Oral treatments and general visits were different in the two time periods (p<0.001). Despite the elevated patient flow, only one patient (0.1%) tested positive for COVID-19 and there were no cases among healthcare staff. CONCLUSIONS: Based on the adopted security protocol we provided continuity of care for all patients and limited the spread of the COVID-19 infection. Twit Text FOAVip Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic ????Int J Gynecol Cancer http://www.kidney.de/pget.php?&tw=1&pmid=33883231 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33883231 #FOAvip English Wikipedia <ref>{{Cite pmid|33883231}}</ref> Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic #MMPMID33883231 Palluzzi E; Corrado G; Marchetti C; Bolomini G; Vertechy L; Bottoni C; Distefano M; Scambia G; Ferrandina G Int J Gynecol Cancer 2021[Aug]; 31 (8): 1154-1158 PMID33883231show ga BACKGROUND: During the COVID-19 pandemic, cancer care had to be reorganized; national and international recommendations were published to manage anticancer treatments safely and to reduce the risk of SARS-CoV-2 infection for patients and health workers. OBJECTIVE: To evaluate whether the adoption of recommendations for the management of patients with gynaecologic cancer receiving treatment during the pandemic resulted in containment of infections and continuing oncologic care. METHODS: Based on the published recommendations, and according to the local Health Direction guidelines, we developed and drafted a security protocol to modify access of patients with gynaecologic cancer to the "Fondazione Policlinico Agostino Gemelli-IRCCS, Rome" between February 1 and April 30, 2020 and compared results with the corresponding 3 months of 2019. RESULTS: Between February and April 2019, we registered 3254 admissions, including 2253 patients receiving intravenous chemotherapies, 298 receiving oral therapies, and 703 having hospital visits. Between February and April 2020, we registered 3213 admissions, including 2221 patients receiving intravenous chemotherapies, 401 receiving oral therapies, and 591 having hospital visits. Oral treatments and general visits were different in the two time periods (p<0.001). Despite the elevated patient flow, only one patient (0.1%) tested positive for COVID-19 and there were no cases among healthcare staff. CONCLUSIONS: Based on the adopted security protocol we provided continuity of care for all patients and limited the spread of the COVID-19 infection. |COVID-19/*epidemiology[MESH] |Female[MESH] |Genital Neoplasms, Female/*therapy[MESH] |Humans[MESH] |Pandemics[MESH]Medical treatment of patients with gynecologic cancer during the COVID(epmc).pdf DeepDyve Pubget Overpricing